Medical Condition News

RSS

Workers exposed to welding fumes may face risk of developing brain damage

New research suggests that workers exposed to welding fumes may be at risk for developing brain damage in an area of the brain also affected in Parkinson's disease. The study is published in the April 6, 2011, online issue of Neurology, the medical journal of the American Academy of Neurology.

7 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111's potential utility as a targeted cancer treatment.

7 Apr 2011

Brazil's Ministry of Health, PharmaPraxis sign deal to manufacture biologic drugs

PharmaPraxis, from Axis Biotec, Cryopraxis, Silvestre Labs and CellPraxis Group, announces the formalization of an agreement with Brazil's Ministry of Health to manufacture biologic drugs.

7 Apr 2011

FDA approves Covidien's PMA application for Pipeline Embolization Device

Covidien, a leading global provider of healthcare products, today announced that it received Premarket Approval from the U.S. Food and Drug Administration for the Pipeline Embolization Device, indicated for the endovascular treatment of adults with large or giant wide-necked intracranial aneurysms in the internal carotid artery from the petrous to the superior hypophyseal segments.

7 Apr 2011

Parkinson's disease linked to increased risk of prostate cancer

University of Utah School of Medicine researchers have found compelling evidence that Parkinson's disease is associated with an increased risk of prostate cancer and melanoma, and that this increased cancer risk also extends to close and distant relatives of individuals with Parkinson's disease.

7 Apr 2011

New PSA test identifies men with prostate cancer more accurately

In a large multi-center clinical trial, a new PSA test to screen for prostate cancer more accurately identified men with prostate cancer -- particularly the aggressive form of the disease -- and substantially reduced false positives compared to the two currently available commercial PSA tests, according to newly published research from Northwestern Medicine.

7 Apr 2011

Study: New cancer drug shrinks tumors in mouse model with few side effects

A study led by researchers at the University of Michigan Comprehensive Cancer Center showed in animal studies that new cancer drug compounds they developed shrank tumors, with few side effects.

7 Apr 2011

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms.

7 Apr 2011

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, today announced that it has successfully completed two Phase 1a clinical studies for AVL-292, its orally-available, selective inhibitor of Bruton's tyrosine kinase (Btk).

6 Apr 2011

Strawberries may slow progression of precancerous lesions in the esophagus

Freeze-dried strawberries may be an alternative to drugs for the prevention of esophageal cancer, according to research presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

6 Apr 2011

Asuragen launches InformThyroid, a panel of molecular markers

Asuragen, Inc. announced today the launch of Inform™Thyroid, a panel of molecular markers used on Fine Needle Aspirates (FNA) of thyroid nodules to aid physicians in the management of thyroid cancer.

6 Apr 2011

ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

Circadian Technologies announced today that its licensee ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, has advised that it has commenced the first Phase 1 clinical trial of its fully-human monoclonal antibody IMC-3C5.

6 Apr 2011

Americans concerned about thyroid cancer development from mammography

Some Americans have expressed concern, due to an erroneous media report, that the small amount of radiation a patient receives from a mammogram may significantly increase the likelihood of developing thyroid cancer. This concern simply is not supported in scientific literature.

6 Apr 2011

BioWa, OBT enter license agreement to advance ADCC programs

BioWa, Inc. and Oxford BioTherapeutics Ltd today announced that they have entered into a license agreement to provide OBT with access to BioWa's patented POTELLIGENT Technology platform for the development of antibody-dependent cellular cytotoxicity enhanced antibodies.

6 Apr 2011

Only half of post-combat military service members having mental health issues seek treatment

Approximately 50 percent of military servicemembers returning from combat duty report experiencing a mental health issue, but only half of them have sought treatment. That is according to a recently released study titled Joining Forces America, a comprehensive survey of more than 1,000 military servicemembers, family members of servicemembers, and mental health professionals.

6 Apr 2011

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

Takeda Pharmaceuticals North America, Inc. announced the presentation of new study results, which evaluated the potential inhibitory effects of certain proton pump inhibitors (PPIs) on Plavix (clopidogrel bisulfate). The results showed that in healthy subjects, clopidogrel's active metabolite and inhibition of platelet function were reduced less by the co-administration of clopidogrel with dexlansoprazole or lansoprazole, rather than esomeprazole.

6 Apr 2011

ICD therapy can improve ischemic cardiomyopathy survival rates

Most patients with ischemic cardiomyopathy and dilated cardiomyopathy who have an implantable cardioverter-defibrillator now live more than seven years and those ICD patients with hereditary heart disease can live for decades, based on a scientific paper that will be presented at the American College of Cardiology Scientific Sessions in New Orleans, April 1-3.

6 Apr 2011

Roswell Park Cancer Institute selected to be part of Cancer Immunotherapy Trials Network

Roswell Park Cancer Institute (RPCI) is one of 27 North American research institutions that have been selected to be part of the Cancer Immunotherapy Trials Network (CITN), a new immunotherapy initiative funded by the National Cancer Institute (NCI). Kunle Odunsi, MD, PhD, FRCOG, FACOG, Director of the Center for Immunotherapy and Chair of Gynecologic Oncology at RPCI, will serve as Principal Investigator of the Institute's role in this collaborative investigative effort.

6 Apr 2011

Researchers develop new stroke rehabilitation devices

Devices which could be used to rehabilitate the arms and hands of people who have experienced a stroke have been developed by researchers at the University of Southampton.

6 Apr 2011

Pancreatic Cancer Action Network, AACR honor NYU School of Medicine's scientist with Fellowship

NYU School of Medicine's Cosimo Commisso, PhD, a postdoctoral fellow in the Department of Biochemistry, is the 2011 recipient of The Pancreatic Cancer Action Network-American Association for Cancer Research Fellowship, a one-year grant designed to support pancreatic cancer research.

6 Apr 2011

Medical Condition News

Workers exposed to welding fumes may face risk of developing brain damage

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

Brazil's Ministry of Health, PharmaPraxis sign deal to manufacture biologic drugs

FDA approves Covidien's PMA application for Pipeline Embolization Device

Parkinson's disease linked to increased risk of prostate cancer

New PSA test identifies men with prostate cancer more accurately

Study: New cancer drug shrinks tumors in mouse model with few side effects

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

Avila announces successful completion of AVL-292 Phase 1a clinical studies for B-cell cancers

Strawberries may slow progression of precancerous lesions in the esophagus

Asuragen launches InformThyroid, a panel of molecular markers

ImClone Systems initiates IMC-3C5 Phase 1 trial in patients with advanced solid tumours

Americans concerned about thyroid cancer development from mammography

BioWa, OBT enter license agreement to advance ADCC programs

Only half of post-combat military service members having mental health issues seek treatment

Results of study evaluating potential inhibitory effects of PPIs on Plavix presented at ACC 2011

ICD therapy can improve ischemic cardiomyopathy survival rates

Roswell Park Cancer Institute selected to be part of Cancer Immunotherapy Trials Network

Researchers develop new stroke rehabilitation devices

Pancreatic Cancer Action Network, AACR honor NYU School of Medicine's scientist with Fellowship

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News